Tables
CRSwNP
20.0(37.0)Without CRSwNP
34.0(63.0)p-value Δ T/0 T/6-12M T/0 T/6-12M ACT
SNOT-22
Low dose OCS regime
Short-term use OCS+
Asthma exacerbation+10.5[9.0–12.5]
70.3±14.4
7.0(35.0)
3.5[2.0–7.0]
4.0[2.0–12.0]22.0[20.0–22.5]
24.1±10.9
3.0(15.0)
0.0[0.0–0.0]
1.0[0.0–1.0]9.0[7.0–11.8]
-
11.0(32.4)
2.0[2.0–4.0]
3.0[2.0–5.0]21.0[19.8–24.0]
-
5.0(14.7)
0.0[0.0–1.5]
1.0[0.0–2.0]0.419
-
0.822
0.031*
0.078Eosinophilia 585.0[300.0-135.0] 100.0[97.5–232.5] 350.0[140.0–740.0] 115.0[65.0–280.0] 0.139 Pre-bronchodilator FEV1 (%) 66.9±24,9 75.2±17,4 58.6±15.8 67.1±15.7 0.983 Data present as n(%), mean±standard deviation or median[range]. T0–beginning of therapy; T/6-12M–6-12 months after; Δ–variation between T/6-12M and T0. +previous year; *p < 0.05
Vol 58 Issue suppl 65
Table of Contents
Impact of biologic therapy in severe asthma with nasal polyps
